Endocrine Abstracts

Introduction: Epigenetic and genetic alterations contribute to cancer initiation and progression. These alterations may be playing a determinant role in the development of pituitary adenomas (PAs). One of these epigenetic processes is the DNA methylation and, specifically, methylation of Tumour Suppressor Genes (TSG). TSG are key elements that allow the maintenance of cellular homeostasis. Due to epigenetic changes are reversible, a better understanding of the underlying epige...

Introduction: The last World Health Organization (WHO) 2016 classification of Pituitary Tumours recommends the determination of transcription factors. During the last few years, silent variants of the main pituitary tumours (PTs) have been described. The mechanisms of silencing of these tumors are still unknown. POU1F1 (Pit1) encodes a member of the POU family of transcription factors that has a relevant role in the differentiation, proliferation and survival of three...

Silent corticotroph tumors (SCT) represent a distinct subtype of pituitary tumors (PT) known for their potential aggressiveness, surpassing other silent PTs like gonadotroph tumors (SGT). Despite their aggressive clinical behavior, the mechanisms underlying their aggressiveness remain unclear. Recent studies in various cancers, such as breast cancer, have implicated the IGF1 axis in the presence of metastases. This study aims to investigate some components of the somatotroph a...

Corticotroph tumours, comprising around 15% of pituitary tumours, express ACTH and other peptides originating from TPIT-lineage adenohypophyseal cells. Their tumorigenesis involves a complex interplay of genetic and epigenetic factors and hormonal and growth factor stimulation. Silent corticotroph tumours (SCT) share immunopositivity for ACTH and TPIT with functioning corticotroph tumours (FCT) but do not exhibit evidence of hypercortisolism. Despite their aggressive growth an...

In our country, as in others, there is a lack of data on the success rate of transsphenoidal surgery for producing pituitary adenomas. We evaluated the results reported in TESSPAIN, a retrospective multicenter nationwide project that includes all the TSS performed in the participating centers in the period between 2018 and 2022, both included. Surgical treatment success is defined according to the published criteria for each disease: normal IGF-1 and GH after 75 g of oral gluc...

Transsphenoidal surgery (TSS) of the hypothalamic-pituitary region is the approach of choice because of its lower morbidity compared to the transcranial approach. However, its results are highly variable and depend on many factors related to the tumor itself, to the medical team, and to technical issues. We review the situation of this procedure in a nationwide retrospective multicenter evaluation. Data were collected from centers participating in the TESSPAIN (TranssphEnoidal...